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Abstract 
Background: The treatment of Parkinson’s disease is often complicated by levodopa-induced dyskinesia (LID). 
Nicotinic acetylcholine receptor agonists can alleviate LID in animal models but may be less effective in conditions of 
severe dopaminergic denervation. While the mechanisms of LID remain incompletely understood, elevated corticos-
triatal levels of the brain-derived neurotrophic factor (BDNF) have been suggested to play a role. Here, female mice 
with near-total unilateral 6-hydroxydopamine-induced nigrostriatal lesions were chronically treated with levodopa, 
and the effects of the α7 nicotinic receptor partial agonist AZD0328 and nicotine on LID were assessed. At the end of 
the experiment, BDNF protein levels in the prefrontal cortex and striatum were measured.
Results: Five-day treatments with three escalating doses of AZD0328 and a 10-week treatment with nicotine failed 
to alleviate LID. BDNF levels in the lesioned striatum correlated positively with LID severity, but no evidence was 
found for a levodopa-induced elevation of corticostriatal BDNF in the lesioned hemisphere. The nicotine treatment 
decreased BDNF levels in the prefrontal cortex but had no effect on striatal BDNF.
Conclusions: The findings suggest that treatment of LID with nicotinic agonists may lose its effectiveness as the dis-
ease progresses, represent further evidence for a role for BDNF in LID, and expand previous knowledge on the effects 
of long-term nicotine treatment on BDNF.
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Background
The primary cause of the motor symptoms of Parkinson’s 
disease is a lack of dopamine in the striatum resulting 
from a loss of dopaminergic neurons in the substantia 
nigra pars compacta (SNC) [1]. Replenishment of the 
lost dopamine with the precursor molecule levodopa 
(l-3,4-dihydroxyphenylalanine) usually provides symp-
tomatic relief [1]. However, complications, including 
abnormal involuntary movements termed levodopa-
induced dyskinesia (LID), often appear as the treatment 
is continued [2].
While current treatment options against LID remain 
suboptimal, including only the multi-target drug aman-
tadine and invasive deep-brain stimulation, preclinical 
studies have revealed many potential treatment tar-
gets [2]. These include neuronal nicotinic acetylcho-
line receptors (nAChRs), widely expressed ion channel 
receptors that modulate most neurotransmission in the 
brain, including nigrostriatal dopaminergic neurotrans-
mission [3, 4]. Extensive preclinical as well as clinical 
studies have described beneficial effects by nAChR 
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ligands on cognition and mood, and preclinical stud-
ies have also extensively investigated nAChR-mediated 
neuroprotective effects in the context of nigrostriatal 
denervation [5]. Furthermore, chronic treatment with 
both selective and non-selective nAChR agonists has 
been shown to alleviate LID in multiple animal models 
[5]. While the specific mechanisms of these antidyski-
netic effects are not completely understood, they are 
hypothesized to be mediated by receptor desensitiza-
tion [5]. In some studies the most effective alleviation 
of LID has been observed in conditions of only partial 
dopaminergic denervation [6–8], suggesting that the 
degree of remaining nigrostriatal innervation may be 
an important determinant of treatment effectiveness.
The pathophysiology of LID has also been the focus 
of many studies and involves numerous mechanisms, 
brain areas and neurotransmitters [2]. Aberrant syn-
aptic plasticity has been suggested to underlie LID, and 
rodent studies have demonstrated that LID is associ-
ated with a loss of bidirectional synaptic plasticity in 
striatal output pathways [9–12]. One important regu-
lator of synaptic plasticity is the brain-derived neuro-
trophic factor (BDNF) [13, 14], raising the hypothesis 
that changes in BDNF levels or function would be asso-
ciated with LID. Indeed, polymorphisms in the Bdnf 
gene have been linked to increased risk of LID in Par-
kinson’s disease patients [15, 16], and striatal over-
expression of BDNF increases susceptibility to LID in 
hemiparkinsonian rodents [17]. Furthermore, increases 
in cortical and striatal Bdnf mRNA were observed in 
hemiparkinsonian rodents after short-term levodopa 
administration and, in the case of the frontal cortex and 
the striatum, were found to be especially prominent in 
the lesioned brain hemisphere [18, 19]. Thus, elevated 
corticostriatal BDNF was suggested to account for LID 
[18].
In this study, we utilized mice with near-total unilateral 
6-hydroxydopamine (6-OHDA) lesions of the dopamin-
ergic nigrostriatal pathway, made possible by intensive 
postoperative care allowing the survival of even the most 
severely lesioned animals, to study whether long-term 
treatment with nAChR agonists can alleviate LID in con-
ditions of severe unilateral dopaminergic denervation. 
The specific nAChR agonists used were the selective 
α7 receptor agonist AZD0328 [20] and the prototypical 
non-selective agonist nicotine. As LID can be associated 
with changes in BDNF, we also investigated the effects 
of the long-term levodopa and nicotine treatments on 
the BDNF protein in the striatum and prefrontal cortex 
(PFC). A frontal cortical area was chosen as denervation-
specific changes in Bdnf mRNA were previously observed 
in the frontal but not the motor-premotor cortices [18, 
19].
Results
See Fig. 1 for the study timeline and Fig. 2 for data char-
acterizing the nigrostriatal lesion model. The study mice, 
unilaterally lesioned with 6-OHDA injections into the 
medial forebrain bundle (MFB), had suffered a severe loss 
of tyrosine hydroxylase (TH)-positive immunostaining 
in the lesioned SNC, with 8.8 ± 0.7% of immunostaining 
remaining at the end of the experiments (n = 10). More 
immunostaining remained in vehicle-treated than in 
nicotine-treated animals (t(8) = 2.51, P = 0.037). Striatal 
dopaminergic denervation could not be assessed in the 
study animals as striatal samples were used for the BDNF 
assay, but in a separate experiment female C57BL/6J 
mice lesioned with identical 6-OHDA injections had suf-
fered a near-total loss of dopamine in the lesioned dorsal 
striatum, as measured by high-performance liquid chro-
matography (HPLC), with only 1.8 ± 0.4% of dopamine 
remaining (n = 5). 
Fig. 1 Timeline of the experiments. Mice were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) injections into the medial forebrain bundle. 
Levodopa (6 mg/kg) together with benserazide (1.5 mg/kg) was administered s.c. daily (Mon–Fri). The α7 nicotinic receptor partial agonist AZD0328 
was administered s.c. at three escalating doses for 1 week (Mon–Fri) per dose. Nicotine was administered continuously in saccharin-sweetened 
drinking water, with the concentration gradually increased to 300 µg/ml over 2 weeks. Severity of levodopa-induced dyskinesia was assessed from 
videos recorded weekly at the indicated time points
Page 3 of 10Leino et al. BMC Neurosci           (2018) 19:77 
Dyskinesia was induced in lesioned animals with daily 
(5  days per week) levodopa (6  mg/kg) and benserazide 
(1.5  mg/kg) s.c. injections. Treatment with escalat-
ing doses of the α7 partial agonist AZD0328 for 5  days 
(Mon–Fri) per dose failed to reduce total dyskinesia 
(Fig.  3a). When LID subtypes were analyzed separately 
(data in Additional file 1), only one statistically significant 
result was observed, where a reduction in axial dyskine-
sia was observed with the lowest dose of 0.03  mg/kg at 
the last measuring time point (100 min) (n = 6 per group; 
treatment × time interaction, F(4,40) = 3.37, P = 0.018).
During treatment with nicotine in drinking water, the 
estimated average daily intake of nicotine at the high-
est concentration was 35.3 ± 9.6  mg/kg, nearly iden-
tical to our previous study where decreased LID was 
observed in partially lesioned nicotine-treated mice [21]. 
In the present study, however, the nicotine treatment 
failed to reduce LID in mice with near-total unilateral 
lesions (Fig. 3b). On the contrary, the nicotine treatment 
appeared to transiently exacerbate dyskinesia during 
the first weeks of the treatment, with a statistically sig-
nificant effect on axial dyskinesia (n = 6 per group; treat-
ment × time interactions: axial dyskinesia, F(8,80) = 3.04, 
P = 0.005; forelimb dyskinesia, F(8,80) = 1.93, P = 0.067; 
orolingual dyskinesia, F(2.7,27.2) = 2.09, P = 0.13). 
No multiple comparisons tests reached statistical 
significance.
At the end of the experiments with nAChR agonists, 
BDNF protein levels in the striatum and PFC were meas-
ured (Fig. 4). No difference in BDNF levels between the 
lesioned and intact hemispheres was observed in either 
brain area. Nicotine treatment had no effect on striatal 
BDNF. BDNF levels in the PFC, however, were decreased 
in nicotine-treated animals (n = 6 per group; main effect 
of treatment: F(1,20) = 9.06, P = 0.007). For analysis of 
correlation between striatal BDNF and dyskinesia sever-
ity, control and nicotine groups were combined as nei-
ther dyskinesia severity at the end of the experiment 
nor striatal BDNF levels differed between groups. BDNF 
levels in the lesioned striatum had a positive linear cor-
relation with total dyskinesia scores at the time of the last 
dyskinesia measurement (n = 12, r = 0.582, P = 0.047). No 
other statistically significant correlations between dyski-
nesia scores and BDNF levels were found (data in Addi-
tional file 1).
Discussion
Nicotinic acetylcholine receptor agonists can alleviate 
LID in animal models of Parkinson’s disease, as shown by 
Quik and colleagues [5] as well as by us [21]. However, 
the extent of dopaminergic denervation may be impor-
tant in determining treatment effectiveness. Indeed, in 
the present study, mice with near-total unilateral nigros-
triatal lesions were treated with the α7 nAChR agonist 
AZD0328 and nicotine without any reduction in LID. 
The finding is partially in line with previous rodent and 
monkey studies, where the most severely lesioned ani-
mals were typically found to be less responsive or even 
completely unresponsive to antidyskinetic nicotine treat-
ment [6–8, 22]. The present finding suggests that a par-
tially intact nigrostriatal pathway may be required or at 
least highly conducive for the treatment of LID with nic-
otine, and that the treatment may thus lose its effective-
ness as the disease progresses.
Nigrostriatal dopaminergic neurons express a large 
variety of both somatodendritic and presynaptic nAChRs 
that modulate striatal dopaminergic neurotransmission 
[3]. Given the critical importance of striatal dopamine for 
Fig. 2 Characterization of the near-total unilateral nigrostriatal 
lesion model. a Representative section, immunostained for tyrosine 
hydroxylase, showing the ventral midbrain dopaminergic areas, 
including the substantia nigra pars compacta (SNC), of a study 
animal lesioned with a 6-hydroxydopamine injection into the 
medial forebrain bundle. b Tyrosine hydroxylase (TH)-positive 
immunostaining remaining in the SNC of the study animals at the 
end of the experiments (n = 10). Less immunostaining remained in 
animals treated chronically with nicotine. c Dopamine remaining 
in the dorsal striatum of a separate set of animals, lesioned with 
identical 6-hydroxydopamine injections, as measured with HPLC 
(n =5). *Difference to vehicle, P < 0.05, t test
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LID [2], these nAChRs stand out as obvious candidates 
for mediators of the antidyskinetic effects by nAChR ago-
nists. Indeed, previous studies have suggested an asso-
ciation between antidyskinetic effects and a dampening 
of nAChR-mediated striatal dopamine release [21, 23]. 
As these nAChRs are mostly lost in a severe nigrostri-
atal lesion, a requirement of partially intact nigrostriatal 
innervation for robust effects by nicotine would not be 
surprising.
In our previous study, we demonstrated that chronic 
nicotine treatment in drinking water had an antidyski-
netic effect in mice with partial unilateral nigrostriatal 
lesions [21]. The previous study utilized the intrastriatal 
6-OHDA lesion model, characterized by less severe and 
topographically more restricted dopaminergic dener-
vation and by LID that is less severe and requires much 
higher levodopa dosages to develop [21, 24]. In our two 
studies, nicotine was administered using the same con-
centration and a similar treatment length, and the aver-
age daily intake of nicotine was practically identical. 
However, the two studies differed in the timing of the 
initiation of drug treatments: in the previous study, the 
nicotine and levodopa treatments were initiated simulta-
neously in naïve animals, while in the present study pre-
established LID was treated with nicotine.
Previous mouse studies have consistently reported 
antidyskinetic effects by nicotine also on pre-estab-




























































Fig. 3 No effect on levodopa-induced dyskinesia by chronic treatment with nicotinic receptor agonists. Mice were lesioned unilaterally with 
6-OHDA, and dyskinesia was pre-induced by 2 weeks of levodopa treatment (6 mg/kg s.c.). a The α7 receptor partial agonist AZD0328 was 
administered s.c. 30 min before levodopa for 1 week per dose (5 days per week), and dyskinesia severity was assessed from video recordings 
captured on the fifth day. No statistically significant differences in total dyskinesia severity between treatment groups were found. b After a 
1-week washout, chronic levodopa treatment (6 mg/kg) was continued and nicotine treatment in drinking water (up to 300 µg/ml) was initiated. 
Dyskinesia severity was assessed from weekly video recordings. Nicotine treatment did not reduce but transiently exacerbated dyskinesia severity, 
with a statistically significant effect on axial dyskinesia (two-way repeated measures ANOVA, treatment × time, P < 0.05). Values represent the 
mean ± SEM of 6 mice
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somewhat high levodopa dose used in the present study 
(6  mg/kg) was previously studied only in experiments 
using nicotine pretreatment [7]. As dopaminergic den-
ervation is the main contributor to sensitization to levo-
dopa and LID [2], in the present study the combination 
of near-total unilateral dopaminergic denervation and 
a high levodopa dose may have led to deeply ingrained 
LID resistant to attenuation by later nicotine treatment. 
Simultaneously, the potential antidyskinetic effects of 
the treatment may have been blunted by the practically 
total unilateral loss of nAChRs expressed on nigrostriatal 
neurons. This situation could be comparable to starting 
nicotine treatment in advanced PD associated with a high 
levodopa dose regime and existing severe LID. Thus, it 
may turn out to be necessary to begin potential clinical 
antidyskinetic treatments with nAChR agonists as early 
as possible.
Another notable difference is that desipramine pre-
treatment was used to inhibit noradrenergic neurode-
generation in the previous study but not in the present 
study. In rats lesioned with intra-MFB 6-OHDA injec-
tions, desipramine pretreatment has resulted in both 
decreased and increased LID [26, 27]. Thus, it is unclear 
what role the desipramine pretreatment may have had in 
the expression of LID in our studies. However, as none 
of the previous rodent studies on antidyskinetic effects 
of nAChR agonists used desipramine [6–8, 25, 28], it is 
unlikely that the lack of desipramine pretreatment would 
explain the lack of efficacy of nicotine in the present 
study.
It is noteworthy that a previous mouse study, utiliz-
ing very similar methods of lesioning, LID induction, 
and chronic nicotine treatment, did observe somewhat 
inhibited LID even when dopamine transporter levels of 
the lesioned striatum were determined to be less than 1% 
of intact levels [7]. While the reason for this discrepancy 
is unclear, it suggests that the sparing of nigrostriatal 
nAChRs may indeed be conducive but not strictly neces-
sary for antidyskinetic effects. Note also that the nicotine 
treatment did have a statistically significant (although 
not alleviating) effect on axial LID also in the present 
study. Thus, also other nAChR populations than those 
expressed on dopaminergic neurons are likely to con-
tribute to the modulation of LID by nAChR ligands. The 
identity of these receptor populations has not so far been 
directly investigated, but they could be potential drug 
targets in the treatment of LID associated with advanced 
PD.
To our knowledge, the antidyskinetic potential of α7 
nAChR agonism has not been previously studied in 
rodents, but monkey studies have reported alleviation of 
LID by various α7 agonists [29–31]. Although AZD0328 
was here administered for only 3 weeks, monkey studies 
have shown significant effects already within 1–2 weeks 
[29–31]. Furthermore, comparable AZD0328 doses as 
used here were previously shown in mice to result in var-
ious behavioral effects, changes in dopamine release, and 
(at the highest dose) maximal brain α7 receptor occu-
pancy [20, 32]. These previous findings suggest that a too 
short treatment time or too low dosages are unlikely to 
explain the present lack of efficacy. Thus, also the lack of 
an antidyskinetic effect by AZD0328 may be explained 
by the near-total unilateral lesion. Note that while α7 












































Striatum Prefrontal cortexa b
Fig. 4 Brain-derived neurotrophic factor (BDNF) protein levels in chronically drug-treated lesioned mice. a No interhemispheric differences in 
BDNF protein levels of the striatum and the prefrontal cortex were found after 15 weeks of levodopa treatment. After 10 weeks of chronic nicotine 
treatment BDNF levels were reduced in the prefrontal cortex of nicotine-treated animals, with no effect on striatal BDNF. Plots show median, 
quartiles, range, and distribution (n = 6 per group). **Main effect of treatment P < 0.01, two-way ANOVA. b BDNF levels in the lesioned striatum were 
positively correlated with dyskinesia severity (r = 0.582, P < 0.05, n = 12)
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associated with relatively severe nigrostriatal damage, 
the loss of striatal innervation was not total [30]. Alter-
natively, α7 agonism may not be antidyskinetic in mice 
in the first place. Note that dyskinetic α7-knockout mice 
respond to nicotine treatment similarly to wild-type 
mice [8], suggesting that in mice α7 agonism does not 
have a major role in nicotine’s antidyskinetic effects. It 
should also be noted that a recent phase 2 clinical study 
observed no significant reduction in LID or parkinson-
ism after 4 weeks of treatment with an α7 receptor partial 
agonist [33].
Based on findings of increased Bdnf mRNA in the 
lesioned brain hemisphere after levodopa administration 
in hemiparkinsonian rats, elevated BDNF in corticostri-
atal neurons has been suggested to underlie levodopa-
induced abnormal movements [18]. In the present study, 
BDNF protein levels in the lesioned striatum and LID 
severity were positively correlated, similar to a previ-
ously reported correlation between striatal Bdnf mRNA 
and LID severity in rats [19]. However, no differences 
in BDNF protein levels between the intact and lesioned 
hemispheres were observed, in contrast to earlier find-
ings on cortical and striatal Bdnf mRNA [18, 19]. The 
contrasting results may be due to the different targets 
of measurement (protein vs. mRNA), or be explained by 
the considerably longer duration of levodopa treatment 
(months vs. days/weeks).
The observed correlation between BDNF and LID 
represents further evidence for a role for BDNF in LID 
pathophysiology, demonstrating that the previously 
reported mRNA level correlation is also present when 
measuring the protein, a relationship which is not always 
predictable in the case of BDNF [34]. However, the pre-
sent findings do not directly support the hypothesis that 
LID is caused by a levodopa-induced elevation of corti-
costriatal BDNF that is further enhanced in conditions of 
dopaminergic denervation [18]. It does remain possible 
that such an elevation, observable in a unilateral animal 
model as an interhemispheric difference, would reflect 
the initial sensitization to levodopa and thus disappear 
after the early phase of the treatment. Note also that 
while striatal BDNF protein is mainly derived from corti-
costriatal glutamatergic afferents, nigrostriatal dopamine 
terminals do represent a minor source of striatal BDNF 
[35]. Unlike in the present study, a near-total unilateral 
depletion of striatal dopamine in 6-OHDA-lesioned rats 
was associated with a modest (14%) decrease in striatal 
BDNF protein levels [35]. While the reason for this dis-
crepancy is unclear, opposite changes in striatal BDNF by 
the nigrostriatal lesion and the levodopa treatment may 
in principle have occurred.
The nicotine treatment had no effect on striatal BDNF 
levels, in line with a previous study on long-term nicotine 
administration via drinking water [36]. Other studies 
have, however, reported both increases and decreases 
in striatal BDNF after chronic nicotine administration 
via various routes [37–39]. In the present study, nico-
tine treatment via drinking water significantly decreased 
BDNF levels in the prefrontal cortex, similarly as in a pre-
vious study on rat frontal cortex utilizing repeated subcu-
taneous nicotine injections [40]. While the previous study 
hypothesized that the nicotine-induced decrease in corti-
cal BDNF was related to a withdrawal stress response, the 
present study included no withdrawal period, making this 
explanation unlikely. Note also that in another rat study a 
nicotine-induced increase in cortical BDNF was reported 
[41]. All in all, the effects of chronic nicotine treatment 
on BDNF appear highly variable and possibly dependent 
on issues such as the route of administration.
Finally, although nicotine has neuroprotective effects 
[5], in the present study the nicotine-treated animals in 
fact had less TH-positive immunostaining remaining in 
the SNC than the control animals. The observation of no 
neurorestoration is in line with a previous study showing 
that nicotine does not have neurorestorative effects in 
rats or monkeys when administered after lesioning [42]. 
The reason for less TH remaining in the nicotine-treated 
animals is unclear. However, note that as the animals 
were randomly re-divided to nicotine and vehicle groups 
after AZD0328 treatment and a washout, the previous 
α7 agonist treatment could in principle confound these 
results.
Conclusions
We show here in hemiparkinsonian mice that levodopa-
induced dyskinesia associated with near-total unilateral 
nigrostriatal dopaminergic denervation can be unrespon-
sive to treatment with nAChR agonists. The results sug-
gest that a partially intact nigrostriatal pathway is highly 
conducive for nAChR-mediated antidyskinetic drug 
effects and that treatment of LID with nAChR agonists 
may lose its effectiveness as the disease progresses. These 
findings may be important to account for when drafting 
potential future strategies for the treatment of late-stage 
Parkinson’s disease with nAChR ligands. In addition, we 
show that BDNF protein levels in the lesioned striatum 
are correlated with LID severity, representing further evi-
dence for a role for BDNF in LID. However, no evidence 
was found for a levodopa-induced elevation in corticos-
triatal BDNF levels of the lesioned hemisphere, suggest-
ing that such elevations observed previously could reflect 
initial sensitization. The present findings also expand 
previous knowledge on the effects of long-term nicotine 
treatment on BDNF. These findings could help steer the 
planning of future studies investigating the aberrant plas-
ticity that is thought to underlie LID.
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Methods
Animals
Adult female C57BL/6J mice (Envigo Netherlands), aged 
28 weeks and weighing 23–31 g at the beginning of the 
study, were group-housed in a temperature- and humid-
ity-controlled environment under a 12 h light/dark cycle. 
Aged and thus relatively weighty mice were used to lessen 
the impact of postoperative weight loss. Only female 
mice were used as male mice are prone to suffer penile 
prolapse complications after a severe 6-OHDA lesion 
[43]. All experiments were conducted following local and 
EU laws and regulations and authorized by the national 
Animal Experiment Board of Finland.
Drugs
Benserazide hydrochloride, 6-hydroxydopamine hydro-
chloride, levodopa methyl ester hydrochloride and 
(–)-nicotine were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). AZD0328 ((2´R)-spiro-[1-azabicy-
clo[2.2.2]octane-3,2´(3´H)-furo[2,3-b]pyridine] D-tar-
trate) was provided free of charge by AstraZeneca 
(Cambridge, MA, USA). Solid drugs were dissolved in 
saline and administered at a volume of 10  ml/kg. Solu-
tions of lidocaine (Orion Pharma, Finland), buprenor-
phine (Temgesic, RB Pharmaceuticals, UK), and 
carprofen (Rimadyl Vet, Pfizer Animal Health, Finland) 
were diluted in saline. The doses of drugs refer to their 
free bases.
Unilateral 6‑OHDA lesion and postoperative care
Stereotactic surgeries were conducted under isoflurane 
anesthesia (4% induction, 2% maintenance) following 
the description of Thiele et  al. [43]. In brief, 6-OHDA 
(3  µg in 0.2  µl of 0.02% ascorbate-saline) was injected 
into the right MFB at the following coordinates rela-
tive to the bregma or the dural surface: A/P − 1.2  mm; 
L/M − 1.1  mm; D/V − 5.0  mm. Lidocaine, buprenor-
phine (0.1 mg/kg, s.c. once before surgery), and carpro-
fen (5 mg/kg, s.c. once after surgery) were used for pain 
relief. Intensive postoperative care included warm saline 
injections to prevent dehydration, alleviating hypother-
mia with heating pads, food pellets softened by soaking 
in water, high-energy palatable diet (Bacon Softies, Bio-
Serv, Flemington, NJ, USA; Nutriplus gel, Virbac, Carros, 
France), and feeding by hand. One animal out of 15 was 
euthanized due to a poor postoperative condition (post-
operative mortality 7%).
Drug treatments
The timeline of the experiments is given in Fig.  1. Lev-
odopa (6  mg/kg) and benserazide (1.5  mg/kg) were 
administered daily (Mon–Fri) as a single s.c. injection. A 
relatively high but not excessive levodopa dose was cho-
sen on the basis of literature [24, 43, 44] and our previ-
ous experience to ensure robust development of all types 
of dyskinetic behaviors in the majority of animals. Two 
mice, however, did not develop LID and were removed 
from the study before the nAChR agonist treatments. 
After 2 weeks of levodopa administration, mice were ran-
domly assigned to two treatment groups (n = 6). While 
continuing the levodopa treatment, one group was also 
treated with the α7 partial agonist AZD0328 [32] at 
escalating doses of 0.03  mg/kg, 0.1  mg/kg, and 1.0  mg/
kg, for 1  week per dose (5  days per week, Mon–Fri), 
administered s.c. 30 min prior to levodopa. The control 
group received saline injections. Dyskinesia severity was 
assessed weekly on the fifth day of administration.
After a 1-week washout (effects of AZD0328 on behav-
ior and receptor expression disappear by 72 h [32]), mice 
were randomly re-divided into two treatment groups 
(n = 6). Levodopa treatment was then resumed, and nico-
tine treatment in saccharin-sweetened drinking water 
(up to 300  µg/ml) was initiated as described previously 
[7]. The concentration of 300  µg/ml was chosen as it is 
the concentration used in previous studies on LID in 
6-OHDA-lesioned mice [7, 8, 21] and as higher concen-
trations do not result in higher nicotine intake due to 
reduced fluid intake [45]. Previous studies in our lab have 
shown that a similar method of administration results in 
mean brain concentrations of nicotine ranging from 243 
to 329  ng/g, sufficient to induce nAChR desensitization 
[46]. Treatment with levodopa and nicotine was contin-
ued for 10 weeks in total with weekly assessments of dys-
kinesia severity, after which the animals were killed and 
the brains collected for biochemical analyses.
Assessment of dyskinesia severity
Following the levodopa injection, the behavior of the 
mouse was video-recorded every 20 min for 60 s over a 
100 min period in a transparent cylinder flanked by two 
vertical mirrors. Dyskinesia severity was assessed from 
the recordings by a person blinded to the treatment con-
dition using previously described scoring criteria [21]. 
Briefly, dyskinetic behaviors were divided into three sub-
types (axial, orolingual, and forelimb) and a score ranging 
from 0 to 4 was assigned for each subtype based on dys-
kinesia frequency and amplitude.
BDNF protein analysis
BDNF protein levels in the striatum and the PFC were 
determined 1  week after the last dyskinesia measure-
ment. Levodopa and nicotine treatments were contin-
ued until the mice were killed by cervical dislocation 4 h 
after the last levodopa administration and the brain dis-
sected on ice. Samples were stored at -80  °C until use. 
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Extraction of proteins was done essentially as previously 
described [47]. A commercial ELISA kit (BDNF Emax 
ImmunoAssay; Promega, Madison, WI, USA) was used 
for the BDNF analyses. The manufacturer’s instructions 
were followed except for two modifications. First, Opta-
coat (ALerCHEK, Springvale, ME, USA) was used as the 
coating buffer, and second, the samples were transiently 
acidified and neutralized [47] without first diluting them 
in DPBS, followed by dilution with Block and Sample 1X 
Buffer.
Tyrosine hydroxylase immunohistochemistry
After the dissection described above, the posterior part 
of the brain was immersed overnight in 4% PFA in PBS at 
+ 4 °C, stored in 20% sucrose in PBS at + 4 °C until freez-
ing in isopentane on dry ice, and stored at − 80 °C. Free-
floating coronal sections of 30  µm thickness were cut 
with a Leica CM3050 cryostat (Leica Biosystems, Wet-
zlar, Germany) and stored at − 20 °C. TH immunostain-
ing was performed essentially as described by Mijatovic 
et al. [48], with the exception that biotinylated protein A 
(prepared using protein A [MP Biomedicals, Santa Ana, 
CA, USA] and N-hydroxysuccinimido-biotin [Sigma-
Aldrich]) was used in place of the secondary antibody to 
reduce background staining. Optical density across the 
SNC was measured as described previously [21].
High‑performance liquid chromatography
HPLC was used to determine the striatal tissue concen-
tration of dopamine in separate female C57BL/6J mice. 
The mice were lesioned with identical 6-OHDA injec-
tions into the MFB and subjected to an approximately 
similar long-term levodopa treatment (12  weeks of 
daily [Mon–Fri] s.c. injections of 3 mg/kg levodopa and 
15 mg/kg benserazide). The collection of samples of dor-
sal striatum and HPLC were performed as described by 
Julku et al. [49].
Data analysis
LID data from the AZD0328 experiment are shown as 
total dyskinesia scores over time in minutes. Total dyski-
nesia was calculated as the sum of the three LID subtype 
scores per time point. For the subtype-specific data see 
Additional file 1. LID data from the nicotine experiment 
are shown as weekly severity scores, separately for each 
subtype, over time in weeks. The weekly dyskinesia score 
was calculated for each dyskinesia subtype as the integral 
(area under the curve) of the animal’s time point scores 
[50], giving the weekly subtype score a theoretical range 
from 0 to 16. Data points missing due to failed levodopa 
administration (affecting 2 out of 120 weekly assess-
ments) were interpolated using linear regression on the 
individual animal’s data. Total weekly dyskinesia scores 
(Additional file 1) were then calculated as the sum of the 
weekly subtype scores.
Immunohistochemical data were analyzed with an 
unpaired Student’s t test. Dyskinesia data were ana-
lyzed with two-way repeated measures analyses of 
variance (ANOVA) [50] with Greenhouse–Geisser cor-
rection for violations of the assumption of sphericity 
followed by Bonferroni’s multiple comparisons tests. 
BDNF data were expressed as percentage of the mean 
of the unlesioned hemisphere of the control group and 
analyzed with two-way ANOVA. Pearson’s correlation 
coefficients were calculated for the correlation between 
BDNF levels and weekly dyskinesia scores at the last 
recording time. All data are represented as either group 
mean ± SEM or as box plots showing group median, 
quartiles, range, and distribution. Statistical analyses 
were performed with IBM SPSS Statistics 24 (IBM, 
Armonk, NY, USA) with the alpha level set at P < 0.05.
Additional file
Additional file 1. All data generated during this study are included within 
a Microsoft Excel file named Additional file 1.xlsx.
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